Section of Preventive Cardiology and Rehabilitation, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, 9500 Euclid Ave., Desk JB-1, Cleveland, OH, 44195, USA.
Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, USA.
ESC Heart Fail. 2021 Aug;8(4):2731-2740. doi: 10.1002/ehf2.13342. Epub 2021 May 1.
In patients with heart failure and reduced ejection fraction (HFrEF), it remains unclear how exacerbated impairments in peak exercise oxygen uptake (V̇O ) caused by coexistent obstructive or restrictive ventilatory defects affect mortality risk. We evaluated in patients with HFrEF, whether demonstrating either an obstructive or restrictive-patterned ventilatory defect on spirometry affects V̇O to yield all-cause mortality risk predicted by V̇O that is spirometry pattern specific.
We retrospectively analysed resting spirometry and treadmill cardiopulmonary exercise testing data of patients with HFrEF (left ventricular ejection fraction ≤ 40%). The study sample (N = 329) was grouped by spirometry pattern: normal [Group 1: N = 101; forced expiratory volume in 1 s (FEV )/forced vital capacity (FVC) ≥ 0.70; FVC ≥ 80% predicted], restrictive without airflow obstruction (Group 2: N = 104; FEV /FVC ≥ 0.70; FVC < 80% predicted), or obstructive (Group 3: N = 124; FEV /FVC < 0.70). Patients were followed up to 1 year for the endpoint of all-cause mortality. V̇O was higher in Group 1 versus Groups 2 and 3 (13.4 ± 4.0 vs. 12.1 ± 3.7 and 12.2 ± 3.3 mL/kg/min, respectively; P = 0.014). Over the 1 year follow-up, n = 9, n = 16, and n = 12 deaths occurred in Groups 1-3, respectively, with corresponding crude survival rates of 88%, 81%, and 92%, respectively (log-rank; P = 0.352). V̇O was associated with all-cause mortality (crude hazard ratio = 0.77; P < 0.001). In multivariate analyses, a significant V̇O -by-spirometry group interaction yielded 1.99 (95% confidence interval, 1.14-3.46) and 2.43 (95% confidence interval, 1.44-4.11) higher mortality risk associated with V̇O in Group 2 versus Groups 1 and 3, respectively.
Demonstrating a restrictive pattern on spirometry yields the severest mortality risk associated with V̇O . Using spirometry to screen patients with HFrEF for ventilatory defects has a potential role in improving risk stratification based on V̇O .
在射血分数降低的心力衰竭(HFrEF)患者中,并存的阻塞性或限制性通气缺陷导致的峰值运动摄氧量(V̇O )恶化程度如何影响死亡率,目前仍不清楚。我们评估了 HFrEF 患者中,肺功能检查显示阻塞性或限制性通气缺陷模式是否会影响 V̇O ,从而产生与 V̇O 相关的、由通气缺陷模式决定的全因死亡率风险。
我们回顾性分析了 HFrEF(左心室射血分数≤40%)患者的静息肺功能和跑步机心肺运动测试数据。研究样本(N=329)按肺功能检查模式分组:正常[第 1 组:N=101;1 秒用力呼气容积(FEV )/用力肺活量(FVC)≥0.70;FVC≥80%预计值]、无气流阻塞的限制性(第 2 组:N=104;FEV/FVC≥0.70;FVC<80%预计值)或阻塞性(第 3 组:N=124;FEV/FVC<0.70)。患者随访 1 年,以全因死亡率为终点。与第 2 组和第 3 组相比,第 1 组的 V̇O 更高(分别为 13.4±4.0、12.1±3.7 和 12.2±3.3 mL/kg/min;P=0.014)。在 1 年的随访中,第 1-3 组分别有 n=9、n=16 和 n=12 例死亡,相应的粗生存率分别为 88%、81%和 92%(对数秩检验;P=0.352)。V̇O 与全因死亡率相关(粗危险比=0.77;P<0.001)。多变量分析显示,V̇O 与肺功能检查组之间存在显著的交互作用,与第 1 组相比,第 2 组和第 3 组的 V̇O 与死亡率相关的风险分别增加 1.99(95%置信区间,1.14-3.46)和 2.43(95%置信区间,1.44-4.11)。
肺功能检查显示限制性模式与 V̇O 相关的死亡率风险最高。使用肺功能检查筛查 HFrEF 患者的通气缺陷可能有助于根据 V̇O 改善风险分层。